CLINICAL TRIALS PROFILE FOR DUOBRII
✉ Email this page to a colleague
All Clinical Trials for Duobrii
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04119102 ↗ | Duobrii in Combination With Biologics | Recruiting | Ortho Dermatologics | Phase 4 | 2019-10-14 | 12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks |
NCT04119102 ↗ | Duobrii in Combination With Biologics | Recruiting | Psoriasis Treatment Center of Central New Jersey | Phase 4 | 2019-10-14 | 12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks |
NCT04720105 ↗ | Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis | Recruiting | Bausch Health Americas, Inc. | Phase 4 | 2020-11-19 | The purpose of this research study is to examine the effect of Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) on plaque type psoriasis of the hands and/or feet. |
NCT04720105 ↗ | Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis | Recruiting | Icahn School of Medicine at Mount Sinai | Phase 4 | 2020-11-19 | The purpose of this research study is to examine the effect of Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) on plaque type psoriasis of the hands and/or feet. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Duobrii
Condition Name
Clinical Trial Locations for Duobrii
Trials by Country
Clinical Trial Progress for Duobrii
Clinical Trial Phase
Clinical Trial Sponsors for Duobrii
Sponsor Name